Search Intelligence

“Bootstrapping robot training with human video is a clever workaround for the physical data shortage, but mapping 27 degrees of human hand freedom to a rigid industrial gripper is an ongoing physics nightmare.”

“The 9.2% weight loss won't dethrone Lilly or Novo outright, but that 1.9% GI dropout rate is a massive commercial weapon for the millions of patients who can't stomach the current GLP-1 side effects.”

“Having a Nobel laureate founder and FDA sign-off means nothing if you can't convince investors to foot the bill for an expensive Phase 3 cell therapy trial.”

“Paying a 42% premium for legacy industrial software in 2026 proves conglomerates would rather buy locked-in factory revenue than gamble on generative AI startups.”

“State prosecutors are finally realizing that nominal fines are just the cost of doing business, so they're explicitly pricing penalties to hurt the stock.”

“When you operate every side of the programmatic ad market, a multi-billion dollar class action is just a deferred monopoly tax.”

“AI platforms mapping evolutionary biology make for excellent pitch decks, but an $845M capital stack means these specific Phase 2 clinical trials have absolutely zero margin for error.”

“Because a state agency brought the case, the company cannot rely on its standard private arbitration clauses, leaving it exposed to uncapped damages decided by a single judge.”

“Launching a massive catalog of 24 distinct robot bodies is a great way to distract from the fact that nobody has figured out the generalizable AI software required to actually operate them.”

“AI can process complex 3D CAD files in seconds, but legacy manufacturers still require hundreds of customer success reps just to convince them to change their workflows.”

“Shifting the vision compute natively to the controller and killing the external PC is the only way physical AI survives the reality of a messy factory floor.”

“Settling nationwide doesn't mean much when a single state decides to drag your decade-old data pipeline failures right back into open court.”

“The US spent years restricting advanced chip exports only to realize China is just renting the compute via API to steal the actual math.”

“Pharma's favorite strategy of buying their way out of a patent cliff hits a wall when the acquired pipeline repeatedly faceplants in Phase 3.”

“Bumping tariffs to 50% doesn't matter much when exporters already know how to route everything through third countries.”

“Billions spent hyping a biological mechanism only to watch the clinical trial completely collapse on first contact with reality.”

“Confidential settlements remain the preferred mechanism for avoiding public jury scrutiny over driver-assistance marketing claims.”

“Prolonging developer trials ensures open-source privacy builders get bankrupted by legal fees long before reaching a verdict.”

“Meta will happily pay a billion-dollar fine if it means preserving the core engagement loops that power its ad revenue.”

“Restricting internal data access to control public narratives is a standard corporate defense, but confirming it on the stand gives prosecutors exactly what they came to court for.”